Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 200

The DOI matches its Crossref record.

Prognostic significance of imaging contrast enhancement for WHO grade II gliomas

Open access
Pallud, Johan, Capelle, Laurent, Taillandier, Luc, Fontaine, Denys, Mandonnet, Emmanuel, Guillevin, Rémy, Bauchet, Luc, Peruzzi, Philippe, Laigle-Donadey, Florence, Kujas, Michèle, Guyotat, Jacques, Baron, Marie-Hélène, Mokhtari, Karima, Duffau, Hugues · 2009 · Neuro-Oncology

Abstract

In this study, we investigated the prognostic value of MRI contrast enhancement (CE) at the time of histological diagnosis specifically in a selected population of WHO grade II gliomas. We reviewed 927 histologically proven WHO grade II gliomas for which contrast-enhanced MR images were available at the time of histological diagnosis. CE patterns were classified into three categories: "patchy and faint," "nodular-like," and "ring-like." CE progression over time was recorded before oncological treatment on successive MR images, when available. CE was present in 143 cases (15.9%), with 93 patchy and faint, 50 nodular-like, and no ring-like patterns. CE areas were time progressive before oncological treatment in 35 of the 56 available cases (62.5%). Regardless of its pattern, the presence of CE was not significantly associated with a worsened prognosis (p = 0.415) by univariate analysis. Only the nodular-like pattern of CE (p < 0.01) and the time-progressive CE (p < 0.001) in the available subgroup proved to be statistically associated with survival since first oncological treatment. The present results show the necessity, in cases of WHO grade II gliomas, to study CE at the time of histological diagnosis and, whenever possible, to follow its progression over time before oncological treatment. Nodular-like CE and time-progressive CE are associated with a worsened prognosis, both suggesting malignant transformation, even though histopathological examination cannot initially disclose signs of malignancy in those areas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1215/15228517-2008-066

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 200

Metadata

Authors
Pallud, J., Capelle, L., Taillandier, L., Fontaine, D., Mandonnet, E., Guillevin, R., Bauchet, L., Peruzzi, P., Laigle-Donadey, F., Kujas, M., Guyotat, J., Baron, M.-H., Mokhtari, K., & Duffau, H.
Venue
Neuro-Oncology
Published
2009-04-01
Volume
11
Issue
2
Pages
176-182
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2143099274
Cited by
200
References
0
FWCI
3.18
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. https://app.cochat.ai/papers/10.1215/15228517-2008-066
The paper
Pallud, J., Capelle, L., Taillandier, L., Fontaine, D., Mandonnet, E., Guillevin, R., Bauchet, L., Peruzzi, P., Laigle-Donadey, F., Kujas, M., Guyotat, J., Baron, M.-H., Mokhtari, K., & Duffau, H. (2009). Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro-Oncology. https://doi.org/10.1215/15228517-2008-066

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.